ATE548384T1 - Ein die angiogenese inhibierendes chimäres protein und dessen verwendung - Google Patents

Ein die angiogenese inhibierendes chimäres protein und dessen verwendung

Info

Publication number
ATE548384T1
ATE548384T1 AT05752254T AT05752254T ATE548384T1 AT E548384 T1 ATE548384 T1 AT E548384T1 AT 05752254 T AT05752254 T AT 05752254T AT 05752254 T AT05752254 T AT 05752254T AT E548384 T1 ATE548384 T1 AT E548384T1
Authority
AT
Austria
Prior art keywords
chimeric protein
inhibiting angiogenesis
protein inhibiting
recombinant
protein
Prior art date
Application number
AT05752254T
Other languages
English (en)
Inventor
Zheng Liu
Original Assignee
Chengdu Kanghong Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologies Co Ltd filed Critical Chengdu Kanghong Biotechnologies Co Ltd
Application granted granted Critical
Publication of ATE548384T1 publication Critical patent/ATE548384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT05752254T 2004-06-08 2005-06-08 Ein die angiogenese inhibierendes chimäres protein und dessen verwendung ATE548384T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200410044965 2004-06-08
PCT/CN2005/000802 WO2005121176A1 (en) 2004-06-08 2005-06-08 Angiogenesis-inhibiting chimeric protein and the use

Publications (1)

Publication Number Publication Date
ATE548384T1 true ATE548384T1 (de) 2012-03-15

Family

ID=35503012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05752254T ATE548384T1 (de) 2004-06-08 2005-06-08 Ein die angiogenese inhibierendes chimäres protein und dessen verwendung

Country Status (13)

Country Link
US (2) US7750138B2 (de)
EP (1) EP1767546B1 (de)
JP (1) JP4680997B2 (de)
KR (1) KR100897379B1 (de)
AT (1) ATE548384T1 (de)
BR (1) BRPI0512286B8 (de)
CA (1) CA2569108C (de)
DK (1) DK1767546T3 (de)
ES (1) ES2381014T3 (de)
PL (1) PL1767546T3 (de)
PT (1) PT1767546E (de)
RU (1) RU2355414C2 (de)
WO (1) WO2005121176A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
HUE055994T2 (hu) 2012-06-01 2022-01-28 Novartis Ag Fecskendõ
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
AU2012101678B4 (en) 2012-07-03 2013-01-24 Novartis Ag Use of device
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JP2016522249A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
US20160129080A1 (en) 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
BR112016000177A2 (pt) 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
JP6071099B1 (ja) 2014-01-25 2017-02-01 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管の新生又は成長を抑制する融合タンパク質及びその用途
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
MX382540B (es) 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017148904A1 (en) 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
WO2018224644A1 (en) 2017-06-08 2018-12-13 Novartis Ag Injection device and injection solution transferring system
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
EP3646887A4 (de) * 2017-06-30 2021-03-24 Korea Advanced Institute of Science and Technology Konjugat aus vegf-grab-protein und arzneimittel und verwendung davon
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2021046245A1 (en) * 2019-09-04 2021-03-11 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN115335529B (zh) * 2019-11-26 2026-07-03 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
US12697439B2 (en) 2019-12-12 2026-08-04 Novartis Ag Injection device and injection solution transferring system
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20230340529A1 (en) * 2020-09-03 2023-10-26 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
EP4145456A1 (de) 2021-09-06 2023-03-08 Bayer AG Vorhersage einer änderung in zusammenhang mit einer makulaflüssigkeit
TW202400214A (zh) 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
EP4588469A4 (de) 2022-09-16 2026-03-04 Qilu Pharmaceutical Co Ltd Stabile hochkonzentrierte selbstpuffernde pharmazeutische zusammensetzung
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
KR20260096819A (ko) 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼
WO2026148214A1 (en) 2025-01-02 2026-07-09 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing buffer free formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
CN101134777A (zh) * 2006-08-31 2008-03-05 苏州思坦维生物技术有限责任公司 可拮抗血管内皮细胞生长因子的人源化的免疫球蛋白的制备方法及其组合应用

Also Published As

Publication number Publication date
PT1767546E (pt) 2012-03-20
KR100897379B1 (ko) 2009-05-14
US20100215655A1 (en) 2010-08-26
JP2008503243A (ja) 2008-02-07
EP1767546B1 (de) 2012-03-07
JP4680997B2 (ja) 2011-05-11
BRPI0512286B8 (pt) 2021-05-25
PL1767546T3 (pl) 2012-07-31
BRPI0512286A (pt) 2008-03-18
RU2006146995A (ru) 2008-07-20
KR20070029204A (ko) 2007-03-13
CA2569108C (en) 2012-08-21
ES2381014T3 (es) 2012-05-22
RU2355414C2 (ru) 2009-05-20
US7750138B2 (en) 2010-07-06
WO2005121176A1 (en) 2005-12-22
BRPI0512286B1 (pt) 2020-03-24
EP1767546A1 (de) 2007-03-28
CA2569108A1 (en) 2005-12-22
US20080206238A1 (en) 2008-08-28
DK1767546T3 (da) 2012-04-23
EP1767546A4 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
PL1767546T3 (pl) Hamujące angiogenezę białka chimeryczne i ich zastosowanie
IL182957A0 (en) Potentiators of glutamate receptors
TW200505875A (en) Novel compounds
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ATE420970T1 (de) Auf il-1-rezeptor beruhende antagonisten sowie herstellungs- und verwendungsverfahren
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
DE60333736D1 (de) Verwendung von miniatursierten vorrichtungen zur herstellung von radiomarkierten verbindungen
SE0302811D0 (sv) Novel compounds
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
ATE514714T1 (de) Hutnfr1-selektive antagonisten
DE60223511D1 (de) Neurotrophe faktoren
ATE494368T1 (de) Polypeptide der gh-61-familie
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
DE602004013557D1 (de) FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
DK1133997T3 (da) Beta-interferon til behandling af immunsygdomme
WO2007045019A3 (en) Polyoleosins
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.
ATE550351T1 (de) Vegf-d-mutanten und ihre verwendung
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
SG146693A1 (en) P185neu-encoding dna and therapeutical uses thereof
DK2186898T3 (da) Blomstrings-induktion
ATE502047T1 (de) T-helper antigenic determinant (thd) peptide
ITRM20050522A1 (it) Proteine omeopatiche per la cura del diabete mellito di tipo 1 0 2 insulinotrattato.
ITMO20020113A1 (it) Procedimento per la decorazione di elementi d'arrredamento, del tipo di mobili o suppellettili